Cardiovascular Disease

License agreement signed with HaptoGuard Inc. for BXT-51072

Published in Obesity and Diabetes Week, October 25th, 2004

OXIS International, Inc., (OTCBB:OXIS) (Nuveau Marche:OXIS) announced that a worldwide exclusive license agreement has been signed with HaptoGuard Inc. for BXT-51072 and related compounds for cardiovascular indications.

HaptoGuard will seek to develop and commercialize OXIS' lead glutathione peroxidase mimic, BXT-51072, for indications ranging from acute coronary syndroms and atherosclerosis to stroke.

Under terms of the agreement, HaptoGuard obtains exclusive worldwide rights to develop, manufacture and market BXT-51072 and related compounds from a specific OXIS library of antioxidant compounds.

HaptoGuard will be responsible for...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week

Source: Obesity and Diabetes Week (2004-10-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry